KRYS - Krystal Biotech Inc Debt to Book Capitalization Ratio

Krystal Biotech, Inc. (KRYS) is expanding within its own product cycle, ensuring a sharp surge in revenue regardless of economic conditions. The company targets patients with severe genetic skin pathologies, receiving payments from insurance providers. This price chart, where the indicator stands at 0.01, complements the profile of a brand recognized by physicians for innovations in gene therapy and the creation of unique therapeutic gels.

KRYS (Krystal Biotech Corp.) Debt to Book Value history from 07/04/2022 to 10/28/2026

Krystal Biotech Inc (KRYS) - metric breakdowns and financial figures

- price and consensus price forecast:

Stock Price Krystal Biotech, Inc.|KRYS - Analyst Consensus Forecast

- market capitalization data:

Market Value Krystal Biotech Corp.|KRYS - Value Adjusted for Debt and Cash

- book capitalization data:

Net Assets per Single Share Krystal Biotech|KRYS - Company Net Assets|Market Capitalization to Book Value Ratio krystalbio.com|KRYS - Company Total Assets

- debt and liquidity data:

Total Debt to Equity Ratio Krystal Biotech, Inc.|KRYS - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Krystal Corp|KRYS - Company Total Debt Obligations|Debt to Book Capitalization Ratio Krystal Biotech Corp.|KRYS - Company Long-Term Debts|Company Short-Term Debts Krystal Biotech

Summary company analytics:Krystal Biotech, Inc. KRYS

For Krystal Biotech, Inc. (KRYS), the ratio of total liabilities to the book value of assets determines the stability of financial leverage amid the rapid commercialization of Vyjuvek. By analyzing the debt-to-enterprise value profile, investors assess the proportion of borrowed capital within the balance sheet structure, allowing them to differentiate operational growth from credit risks during shifts in market cycles.

Competitors of Krystal Biotech, Inc.